AZD4747, that shows promise in treating tumors with the KRAS G12C mutation.

KRAS G12C inhibitors that can penetrate the brain have a differentiated clinical advantage.

For most patients with severe depression, monoamine-targeted first or second-line treatments often cannot achieve sufficient therapeutic effects.

The world's first non-hormonal targeted drug for the treatment of moderate to severe vasomotor symptoms (VMS) caused by menopause.

What are small nucleic acid drugs, and why are they highly valued by industry giants?

The report offers a comprehensive overview of the latest advancements in the pharmaceutical industry.

The history of Merck, also known as MSD, can be traced back 354 years to 1668, making it a legendary presence among multinational pharmaceutical companies.

Vilobelimab is a monoclonal antibody that targets C5a. It is developed by InflaRx NV for the treatment of COVID-19, pyoderma gangrenosum, anti-neutrophil cytoplasmic antibody-associated vasculitis, recurrent cutaneous squamous cell carcinoma, cutaneous squamous cell carcinoma, squamous cell carcinoma, pyoderma gangrenosum with vasculitis, granulomatosis with polyangiitis, and microscopic polyangiitis.

Why do major pharmaceutical companies love BTK? This is closely related to its immense market potential, wide range of indications, clinically prominent efficacy, and safety.

we are excited to announce the addition of clinical trial outcomes to Synapse Premium!

The report offers a comprehensive overview of the latest advancements in the pharmaceutical industry.

Benegrastim is a fusion protein targeting CSF-3R (GCSFR). It is used for the treatment of neutropenia, fever, breast cancer, Parkinson's disease, and other conditions.